Aldeyra Therapeutics Stock Forum

Here are the levels on ALDX.
Larger Image: tradingview.com...
$Aldeyra Therapeutics (ALDX.US)$  

$Aldeyra Therapeutics (ALDX.US)$ Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial For Reproxalap Ophthalmic Solution In Treating Dry Eye Disease; Statistically Superior For Ocular Discomfort; NDA Resubmission Anticipated In 2024

$Aldeyra Therapeutics (ALDX.US)$ 🤫

$Aldeyra Therapeutics (ALDX.US)$ Aldeyra: No Safety Signals Observed in Clinical Trial, and Reproxalap Was Observed to Be Well Tolerated

$Aldeyra Therapeutics (ALDX.US)$ 🤔

$Aldeyra Therapeutics (ALDX.US)$ Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease expected to submit to FDA in  2H

$Aldeyra Therapeutics (ALDX.US)$
NEWS
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Positive
Enrollment of the first patient in the Phase 3 clinical trial for reproxalap indicates progress in Aldeyra Therapeutics' efforts to address dry eye disease.
Potential resubmission of the NDA for reproxalap in the second half of 2024 demonstrates the company's commitment to advancing in...

$Aldeyra Therapeutics (ALDX.US)$ Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

$Aldeyra Therapeutics (ALDX.US)$ATTENTION LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS
Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of Aldeyra have breached their fiduciary duties owed to the company.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to Januar...